Sacubitril/Valsartan Dose Titration Strategy for Patients on 24/26 mg
For patients currently on 24/26 mg of sacubitril/valsartan (Entresto), the dose should be doubled to 49/51 mg twice daily after 2-4 weeks, followed by further uptitration to the target dose of 97/103 mg twice daily after another 2-4 weeks, as tolerated by the patient. 1
Understanding the Current Dose
- 24/26 mg twice daily is the lowest available dose of sacubitril/valsartan and is typically used as:
Recommended Titration Algorithm
Current dose: 24/26 mg twice daily
First uptitration step (after 2-4 weeks on current dose)
Second uptitration step (after 2-4 weeks on 49/51 mg)
- Increase to target dose of 97/103 mg twice daily 1
- Continue monitoring for adverse effects
Maintenance phase
- Maintain at highest tolerated dose, preferably the target dose of 97/103 mg twice daily 5
Monitoring During Titration
- Blood pressure: Watch for symptomatic hypotension (SBP <100 mmHg) 3, 4
- Renal function: Monitor for doubling of serum creatinine or eGFR decline 3
- Electrolytes: Check for hyperkalemia (K+ ≥5.5 mmol/L) 3
- Symptoms: Assess for dizziness, especially upon standing 6
Special Considerations
If patient experiences intolerable side effects during uptitration:
If hypotension limits uptitration:
- Assess for volume depletion and consider reducing diuretic dose if no signs of congestion 6
- Consider temporarily reducing or discontinuing other non-essential antihypertensive medications 6
- Educate patients that mild dizziness upon standing may be transient and doesn't necessarily require dose reduction 6
Clinical Outcomes of Proper Titration
- Achieving the target dose of 97/103 mg twice daily is associated with:
- Improved survival and reduced hospitalizations 7, 2
- Progressive improvement in exercise capacity starting during the uptitration period 8
- Positive left ventricular reverse remodeling with increased ejection fraction 8
- Reduction in NT-proBNP levels, indicating improved hemodynamic status 9
- Delayed but significant reduction in sST2 levels, suggesting anti-fibrotic effects 9
Common Pitfalls to Avoid
- Failure to uptitrate: Only about 27% of patients achieve target dose within 6 months in real-world practice 10
- Premature discontinuation: 34% of patients do not have an active prescription at 6 months 10
- Inadequate monitoring: Lack of follow-up during titration may lead to unnecessary discontinuation 11
- Not recognizing early benefits: Improvements in cardiac function begin during the uptitration phase, not just after reaching target dose 8, 9
Patient Populations Requiring Special Attention
- Black patients, those with high comorbidity burden (≥8 comorbidities), and recently hospitalized patients have lower adherence rates and may need more support during titration 10
- Patients with low baseline blood pressure may still tolerate and benefit from sacubitril/valsartan, but require more careful titration 6